[CAS NO. 1314873-02-3] BPO-27racemate
PRODUCTS SPECIFICATIONS [1314873-02-3]
DESCRIPTION [1314873-02-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 548.34 |
| Molecular Formula | C26H18BrN3O6 |
| SMILES | O=C(C1=CC=C(OC(C2=CC=C(Br)O2)C3=C(N(C)C4=O)C(C(N4C)=O)=C(C5=CC=CC=C5)N36)C6=C1)O |
1 Publications Citing Use of MCE
Summary
BPO-27 racemate is a potent CFTR inhibitor with an IC 50 of 8 nM.
IC50 & Target
IC50: 8 nM [1]
In Vitro
The benzopyrimido-pyrrolo-oxazinedione BPO-27 is an analogue of PPQ-102, which inhibits CFTR with an IC 50 of 8 nM. The R enantiomer of BPO-27 inhibits CFTR chloride conductance with an IC 50 of 4 nM, while S enantiomer is inactive. In vitro metabolic stability in hepatic microsomes shows both enantiomers as stable, with less than 5% metabolism in 4 h [1] . (R)-BPO-27 binds near the canonical ATP binding site. Whole-cell patch-clamp studies shows linear CFTR currents with a voltage-independent (R)-BPO-27 block mechanism. At a concentration of (R)-BPO-27 that inhibits CFTR chloride current by 50%, the EC 50 for ATP activation of CFTR increases from 0.27 to 1.77 mM [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Following bolus interperitoneal administration in mice, serum (R)-1 decays with t 1/2 ≈ 1.6 h and gives sustained therapeutic concentrations in kidney [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 16.67 mg/mL ( 30.40 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.8237 mL | 9.1184 mL | 18.2369 mL |
| 5 mM | 0.3647 mL | 1.8237 mL | 3.6474 mL |
| 10 mM | 0.1824 mL | 0.9118 mL | 1.8237 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 1.67 mg/mL (3.05 mM); Clear solution
References
- [1] Snyder DS, et al. Absolute Configuration And Biological Properties of Enantiomers of CFTR Inhibitor BPO-27. ACS Med Chem Lett. 2013 May 9;4(5):456-459.
- [2] Kim Y, et al. Benzopyrimido-pyrrolo-oxazine-dione (R)-BPO-27 Inhibits CFTR Chloride Channel Gating by Competition with ATP. Mol Pharmacol. 2015 Oct;88(4):689-96.